PIPAC for Peritoneal Carcinomatosis in Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
This study is looking at the safety of a treatment called pressurized intraperitoneal aerosol chemotherapy (PIPAC) for patients with certain cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis). These cancers include ovarian, uterine, appendiceal, colorectal, or gastric (stomach) cancer. PIPAC is a minimally invasive procedure that delivers chemotherapy drugs like cisplatin and doxorubicin directly into the abdomen. The study will also look at how well patients respond to the treatment and if they can have further surgery. About 49 people are planned to join this study. The study is currently unclear about its recruitment status.
- Study design
- This is an interventional study planning to enroll 49 participants. It is designed to evaluate the safety of PIPAC in different groups of patients with peritoneal carcinomatosis.
- What's involved
- You would undergo biopsies and receive chemotherapy drugs like cisplatin, doxorubicin, and fluorouracil. The study will monitor for side effects for up to 18 weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track adverse events from day 1 of treatment until week 18. Efficacy will be assessed at baseline, week 10, 6 weeks after completing treatment, and at 18 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT04329494
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Recruiting
PHASE1Ages 18+InterventionalTreatmentCity of Hope Medical CenterInvestigator-initiated
~49 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:BiopsyCisplatinDoxorubicinFluorouracilIntraperitoneal ChemotherapyIrinotecan
At a glance
Recruiting sites
2 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dose limiting toxicities
Measured over Up to 18 weeks
+1 more outcome measured
Conditions
Where it's being run
3 sites across 3 statesCalifornia1
Florida1
New York1
Study leadership
- Thanh H Dellinger, MD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center
- Mustafa Raoof, MD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Documented informed consent of the participant and/or legally authorized representative
Patients must have histologically confirmed ovarian, uterine, gastric, appendiceal or colorectal cancer with PC
Prior IP chemotherapy is permitted
Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\< 2
Absolute neutrophil count (ANC) \>= 1500/mm\^3
Platelets \>= 100,000/mm\^3
Hemoglobin \>= 9 g/dl
Serum total bilirubin =\< 1.5 x upper limit of normal (ULN)
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) and aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2.5 x ULN, unless liver metastases (Arm 1) are present or unless patients is know to have chronic liver disease (hepatitis) in which case AST and ALT must be =\< 5 x ULN
Alkaline phosphatase =\< 2 x ULN
Serum creatinine (sCr) =\< 1.5 x ULN, or creatinine clearance (Ccr) \>= 40 ml/min as calculated by the Cockcroft-Gault formula
No contraindications for a laparoscopy
The peritoneal disease does not have to be measurable by RECIST 1.1 but needs to be visible on cross sectional imaging or diagnostic laparoscopy
Patients must have progressed on at least one evidence-based chemotherapeutic regimen (Arm 1 and 2). For Arm 3, patients should have stable or responsive disease on at least 4 months first-line systemic chemotherapy
For patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Women of childbearing potential (WOCBP) and male patients with WOCBP partner must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Post menopause is define as:
Amenorrhea \>= 12 consecutive months without another cause or
For women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL
Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential
PIPAC access is feasible
There is room for aerosol therapy
There is no evidence of impending bowel obstruction
=\< 5 L of ascites
Not a candidate for cytoreduction and HIPEC
Exclusion
Gastric and colorectal/appendiceal:
Extra-peritoneal metastatic disease
Arm 1 (ovarian, uterine, gastric): Previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones
Arm 2 (colorectal/appendiceal): Known dihydropyrimidine dehydrogenase deficiency (DPD) deficiency
Arm 2 (colorectal/appendiceal): Bowel obstruction requiring nasogastric tube, percutaneous endoscopic gastrostomy or exclusive total parenteral nutrition
Arm 2 (colorectal/appendiceal): Prior unanticipated severe reaction or hypersensitivity to platinum based compounds
Arm 2 (colorectal/appendiceal): Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1), with the exception of alopecia, hearing loss, or non-clinically significant laboratory abnormalities. Grade 2 peripheral neuropathy is permitted
Arm 2 (colorectal/appendiceal): Life expectancy of less than 6 months
Arm 2 (colorectal/appendiceal): Chemotherapy or surgery within the last 4 weeks prior to enrollment (6 weeks for prior bevacizumab therapy). Five half-lives for other anti-cancer agents
Arm 2 (colorectal/appendiceal): Previous anaphylactic reaction to the chemotherapy drug used
Arm 2 (colorectal/appendiceal): Patients may not be receiving any other investigational or concurrent anti-cancer agents
Arm 2 (colorectal/appendiceal): Ascites due to decompensated liver cirrhosis; portal vein thrombosis
Arm 2 (colorectal/appendiceal): Simultaneous tumor debulking with gastrointestinal resection
Arm 2 (colorectal/appendiceal): Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias, severe renal impairment, myelosuppression, or severe hepatic impairment
Arm 2 (colorectal/appendiceal): Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system
Arm 2 (colorectal/appendiceal): Involvement in the planning and conduct of the study
Arm 2 (colorectal/appendiceal): Pregnancy
Arm 2 (colorectal/appendiceal): Patients with psychiatric illness/social situations that would limit compliance with study requirements
Arm 2 (colorectal/appendiceal): New York Heart Association (NYHA) class 3 or 4; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months
Arm 2 (colorectal/appendiceal): Major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug
Arm 2 (colorectal/appendiceal): Exclusive total parenteral nutrition
Arm 2 (colorectal/appendiceal): Prior intra-abdominal aerosol chemotherapy
Arm 3 (colorectal/appendiceal): Progression on first- AND second-line systemic therapy
Arm 3 (colorectal/appendiceal): Hematologic toxicities requiring significant dose reductions while on systemic chemotherapy
Arm 3 (colorectal/appendiceal): Intolerance to prior 5-FU at 2400mg/m\^2 IV every 2 weeks or to irinotecan at 180mg/m\^2. Intolerance is defined as the need of significant dose reduction or treatment interruption of \> 1 week due to toxicity
Arm 3 (colorectal/appendiceal): Known DPD deficiency
Arm 3 (colorectal/appendiceal): Bowel obstruction requiring nasogastric tube, percutaneous endoscopic gastrostomy or exclusive total parenteral nutrition
Arm 3 (colorectal/appendiceal): Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \> grade 1), with the exception of alopecia, hearing loss, or non-clinically significant laboratory abnormalities. Grade 2 peripheral neuropathy is permitted
Arm 3 (colorectal/appendiceal): Life expectancy of less than 6 months
Arm 3 (colorectal/appendiceal): Chemotherapy or surgery within the last 2 weeks prior to enrollment (6 weeks for prior bevacizumab therapy). Five half-lives for other anti-cancer agents
Arm 3 (colorectal/appendiceal): Previous anaphylactic reaction to the chemotherapy drug used
Arm 3 (colorectal/appendiceal): Patients may not be receiving any other investigational anti-cancer agents
Arm 3 (colorectal/appendiceal): Ascites due to decompensated liver cirrhosis; portal vein thrombosis
Arm 3 (colorectal/appendiceal): Simultaneous tumor debulking with gastrointestinal resection
Arm 3 (colorectal/appendiceal): Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias, severe renal impairment, myelosuppression, or severe hepatic impairment
Arm 3 (colorectal/appendiceal): Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system
Arm 3 (colorectal/appendiceal): Involvement in the planning and conduct of the study
Arm 3 (colorectal/appendiceal): Pregnancy
Arm 3 (colorectal/appendiceal): Patients with psychiatric illness/social situations that would limit compliance with study requirements
Arm 3 (colorectal/appendiceal): New York Heart Association (NYHA) class 3 or 4; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months
Arm 3 (colorectal/appendiceal): Major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug
Arm 3 (colorectal/appendiceal): Exclusive total parenteral nutrition
Arm 3 (colorectal/appendiceal): Prior intra-abdominal aerosol chemotherapy
What this trial measures
- Dose limiting toxicitiesUp to 18 weeks
Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Summarized by type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment, and reversibility or outcome.
- Incidence of adverse eventsFrom day 1 of protocol therapy until week 18
Assessed using CTCAE v.5.0. Summarized by grade and attribution. Post-surgical complications will be assessed by Clavien-Dindo classification.